Impact of HFE gene variants on iron overload, overall survival and leukemia-free survival in myelodysplastic syndromes

摘要

Although iron overload is a clinical challenge, little is known about the clinical impact of HFE -variants in myelodysplastic syndromes (MDS) to date. We analyzed the HFE status in 167 MDS patients and 494 healthy controls. One or more of the 3 HFE -variants (H63D, C282Y, S65C) were found in 65/167 (38.9%) MDS patients and in 164/494 (33.2%) controls. At diagnosis, the median serum ferritin levels were higher in MDS patients with HFE -variants (409 μg/L; range: 23-7415) compared to those without HFE -variants (346.5 μg/L; range: 10-5450) (P=0.62). Moreover, ‘ HFE -mutated’ patients had a slightly faster increase in serum ferritin in follow up examinations. The percentage of patients with HFE -variants was higher in refractory anemia (RA) (22/53=41.5%) or RA with ring sideroblasts (RARS) (17/39=43.6%) compared to RA with excess of blasts (RAEB) (16/46=34.8%) or RAEB in transformation (RAEB-T) (5/17=29.4%). Differences were also detectable when comparing low- and high-risk MDS variants defined by the World Health Organization classification. There was no significant correlation between HFE -variants and MDS-related somatic mutations. Progression-free survival was substantially longer in patients with HFE -variants compared to those without HFE -variants H63D and C282Y (P=0.089). Together, the HFE -variants H63D and C282Y are frequently detected in Austrian MDS patients. These patients have substantially higher ferritin levels at diagnosis, accumulate iron slightly faster and have a better progression-free survival than non-mutated patients.